Thomas Lars Andresen has a background in biomaterials and biological engineering. He has started several companies, such as Nanovi in 2012, Monta Biosciences in 2014, and the Boston-based Torque Therapeutics in 2015. Academically, Thomas has received multiple research prizes, including the Elite Research Prize from the Danish Ministry of Science, published more than 160 research articles, and filed approximately 40 patent applications. He spent more than two years in Boston as a full-time CSO of Torque Therapeutics, and he was instrumental in merging the company with Cogen to form Repertoire Immune Medicines. He was the lead on three IND filings in the US and one in Europe and led four distinct technologies into clinical trials, one of which is now commercialized in Europe. He holds positions as an Adjunct Professor at the Danish Technical University and CEO of T-Cypher Bio.